Health

Exactech Expands Global Direct Operations with Acquisition of Italian Distributor

Thursday, November 21, 2019 - 9:00pm

The purchase included all shares of the Province of Brescia-based importer and distributor of Exactechs orthopaedic implants, instrumentation and advanced surgical technologies.

Key Points: 
  • The purchase included all shares of the Province of Brescia-based importer and distributor of Exactechs orthopaedic implants, instrumentation and advanced surgical technologies.
  • According to Exactech Senior Vice President of Global Sales Stuart Kleopfer, Exactech Italia has been a key strategic partner for the past eight years, distributing our knee, hip and shoulder replacement systems, as well as our ExactechGPS computer-assisted surgery technology.
  • Exactech Italia employs distribution and sales professionals who provide products through independent agencies throughout the country.
  • With this acquisition, Exactech now has direct operations in eight global markets with distribution in more than 35 countries.

Oticon Celebrates Winners of the 21st Annual Oticon Focus on People Awards

Thursday, November 21, 2019 - 8:19pm

Oticon, Inc. announced the winners of the 21st Annual Oticon Focus on People Awards , a program dedicated to honoring individuals with hearing loss and the hearing care professionals who open new possibilities for the hearing impaired community.

Key Points: 
  • Oticon, Inc. announced the winners of the 21st Annual Oticon Focus on People Awards , a program dedicated to honoring individuals with hearing loss and the hearing care professionals who open new possibilities for the hearing impaired community.
  • Tony puts that passion to work by openly discussing his use of hearing aids to promote inclusion among his students and athletes.
  • All second and third place winners receive a cash prize and a Certificate of Recognition from Oticon.
  • To read the stories of the 21st Annual Oticon Focus on People Awards winners, visit www.Oticon.com/FOP .

Enanta Pharmaceuticals Reports Financial Results for its Fiscal Fourth Quarter and Year Ended September 30, 2019

Thursday, November 21, 2019 - 9:00pm

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical stage biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today reported financial results for its fiscal fourth quarter and year ended September 30, 2019.

Key Points: 
  • Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical stage biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today reported financial results for its fiscal fourth quarter and year ended September 30, 2019.
  • Fiscal Fourth Quarter and Year Ended September 30, 2019 Financial Results
    Total revenue of $51.3 million for the three months ended September 30, 2019 consisted of royalty revenue derived primarily from worldwide net sales of AbbVies hepatitis C virus (HCV) regimen MAVYRET/MAVIRET.
  • The decrease in royalty revenue quarter over quarter was driven by lower HCV product sales as reported by AbbVie.
  • Enanta plans to issue its fiscal first quarter 2020 financial results press release, and hold a conference call regarding those results, on February 6, 2020.

Klick Health Welcomes Carl Turner as Chief Brand Strategy Officer

Thursday, November 21, 2019 - 8:30pm

Klick Health today announced that seasoned healthcare marketing strategist Carl Turner has joined its growing team as Chief Brand Strategy Officer in a move that will help cement the independent hypergrowth agencys position as the leading creative powerhouse and commercialization partner in the life sciences industry.

Key Points: 
  • Klick Health today announced that seasoned healthcare marketing strategist Carl Turner has joined its growing team as Chief Brand Strategy Officer in a move that will help cement the independent hypergrowth agencys position as the leading creative powerhouse and commercialization partner in the life sciences industry.
  • Levy, Chief Medical Officer Holly Henry, and EVP, Activation Strategy Cam Bedford will work alongside Turner collectively leading one of the most dynamic and talented strategy and creative partnerships in life sciences.
  • Obsessed with creating unorthodox approaches to strategy, unique stories for brands, and inspired strategy teams, Turner brings almost two decades of experience in brand strategy, research, and analytics to Klick.
  • Turner spent the past five years at Publicis Health, most recently as Managing Partner & Chief Strategy Officer of Razorfish.

Hyland Healthcare Advisory Councils Surface Top Tech Trends

Thursday, November 21, 2019 - 4:47pm

CLEVELAND, Nov. 21, 2019 /PRNewswire/ -- Hyland Healthcare , a leading provider of connected healthcare solutions for organizations across the globe, and three of the company's advisory councils came together during Hyland's annual user conference, CommunityLIVE , to discuss leading issues in healthcare IT.

Key Points: 
  • CLEVELAND, Nov. 21, 2019 /PRNewswire/ -- Hyland Healthcare , a leading provider of connected healthcare solutions for organizations across the globe, and three of the company's advisory councils came together during Hyland's annual user conference, CommunityLIVE , to discuss leading issues in healthcare IT.
  • The three advisory councils consist of Hyland Healthcare customers who represent large healthcare systems to small community hospitals, and utilize a variety of electronic medical records and other technology.
  • "The importance of Hyland Healthcare's advisory councils can't be overstated.
  • We apply findings from our advisory councils to help all our customers address key initiatives like patient engagement and operational efficiencies to improve today's healthcare delivery system."

Fujifilm Presents Comprehensive Enterprise Imaging Portfolio At RSNA 2019

Thursday, November 21, 2019 - 4:36pm

LEXINGTON, Mass., Nov. 21, 2019 /PRNewswire/ -- (Booth #4111) -- FUJIFILM Medical Systems U.S.A., Inc. , a leading provider of Enterprise Imaging and Informatics solutions, and part of the larger Fujifilm Healthcare portfolio, will demonstrate its full Synapse portfolio and debut its latest advancement in Enterprise Imaging, Synapse 7x*, at the Radiological Society of North America's (RSNA) annual meeting to be held from December 1-5, 2019 at McCormick Place in Chicago, IL.

Key Points: 
  • LEXINGTON, Mass., Nov. 21, 2019 /PRNewswire/ -- (Booth #4111) -- FUJIFILM Medical Systems U.S.A., Inc. , a leading provider of Enterprise Imaging and Informatics solutions, and part of the larger Fujifilm Healthcare portfolio, will demonstrate its full Synapse portfolio and debut its latest advancement in Enterprise Imaging, Synapse 7x*, at the Radiological Society of North America's (RSNA) annual meeting to be held from December 1-5, 2019 at McCormick Place in Chicago, IL.
  • Synapse Cloud Services Ascalable environment shaped to host and manage the Synapse Enterprise Imaging portfolio.
  • From an unrivaled selection of digital X-ray systems, to the comprehensive Synapse Enterprise Imaging portfolio, to full-field digital mammography systems with digital breast tomosynthesis, and computed tomography solutions for oncology and radiology applications, Fujifilm has products that are ideal for any size imaging environment.
  • FUJIFILM Medical Systems U.S.A., Inc. Endoscopy supplies high quality, technologically advanced endoscopic imaging solutions and devices to the medical field.

Outlook on the Global Market for Gluten-free Products, 2019 to 2024 - Attractive & Sustainable Packaging with Clean Labels is Gaining Consumer Attention

Thursday, November 21, 2019 - 4:30pm

The global gluten-free products market size was valued at US$ 4.5 Billion in 2018.

Key Points: 
  • The global gluten-free products market size was valued at US$ 4.5 Billion in 2018.
  • Looking forward, the global gluten-free products market is projected to reach a value of US$ 6.7 Billion by 2024, registering a CAGR of 6.7% during 2019-2024.
  • They are also manufacturing attractive and sustainable packaging with clean labeling to gain consumer attention, which is expected to impact the market positively.
  • How has the global gluten-free products market performed so far and how will it perform in the coming years?

CALQUENCE Approved in the US for Adult Patients With Chronic Lymphocytic Leukemia

Thursday, November 21, 2019 - 7:54pm

Fatal and serious infections, including opportunistic infections, have occurred in patients with hematologic malignancies treated with CALQUENCE.

Key Points: 
  • Fatal and serious infections, including opportunistic infections, have occurred in patients with hematologic malignancies treated with CALQUENCE.
  • In clinical trials, major hemorrhage occurred in 2.7% of patients taking CALQUENCE without antithrombotic agents and 3.6% of patients taking CALQUENCE with antithrombotic agents.
  • Adverse reactions led to CALQUENCE dose reduction in 7% and 4% of patients in the CALQUENCE plus obinutuzumab arm (N=178) and CALQUENCE monotherapy arm (N=179), respectively.
  • In the US, CALQUENCE (acalabrutinib) is indicated for the treatment of adult patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).

Life Spine Announces FDA 510(k) Clearance of the Award-winning LONGBOW® Titanium Lateral Expandable Spacer System

Thursday, November 21, 2019 - 7:28pm

Life Spine, a medical device company that designs, develops, manufactures and markets products for the surgical treatment of spinal disorders, announced today that it has received clearance from the U.S. Food & Drug Administration (FDA) to market the LONGBOW Titanium Lateral Expandable Spacer System.

Key Points: 
  • Life Spine, a medical device company that designs, develops, manufactures and markets products for the surgical treatment of spinal disorders, announced today that it has received clearance from the U.S. Food & Drug Administration (FDA) to market the LONGBOW Titanium Lateral Expandable Spacer System.
  • We are thrilled to be releasing a Titanium version of the first to market LONGBOW Expandable Lateral Spacer System which was designed to accomplish previously unmet surgical goals, said Rich Mueller, Chief Operating Officer for Life Spine.
  • The LONGBOW system is available in lengths ranging from 45-60mm, heights from 9mm-15mm, 0 and 7 lordotic options and widths that expand from 15mm-27mm anterior to posterior.
  • The system is supported by Life Spines full portfolio of Lateral solutions including the CENTRIC Plier Style Retractor System, Lateral Disc Prep Instruments and the SENTRY Lateral Plating Systems.

BRUKINSA™ (zanubrutinib) Approved for the Treatment of Mantle Cell Lymphoma, Available from Onco360

Thursday, November 21, 2019 - 7:13pm

As a specialty pharmacy dedicated to serving people with cancer, Onco360 is pleased to be one of a few pharmacies bringing this new innovative treatment to MCL patients.

Key Points: 
  • As a specialty pharmacy dedicated to serving people with cancer, Onco360 is pleased to be one of a few pharmacies bringing this new innovative treatment to MCL patients.
  • According to the American Cancer Society , Mantle cell lymphoma is a type of non-Hodgkins lymphoma representing 3-10% of all non-Hodgkins lymphomas in the United States.
  • By the time it is diagnosed, mantle cell lymphoma has usually spread to the lymph nodes, bone marrow and other organs.
  • Across both trials, BRUKINSA achieved an ORR, which is the sum of complete responses and partial responses, of 84%.